Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.695
+0.025 (+0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
March 31, 2024
Learn the potency of lesser-known stocks and explore their fundamental edge in technology distribution, food retail, and biotechnology.
Via
InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
March 11, 2024
Via
Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
Recap: Vistagen Therapeutics Q3 Earnings
February 13, 2024
Via
Benzinga
VistaGen Therapeutics's Earnings: A Preview
February 12, 2024
Via
Benzinga
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
February 28, 2024
Via
Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
3 Revolutionary Biotech Stocks Poised for 10X Surge
February 19, 2024
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.
Via
InvestorPlace
VistaGen Therapeutics Earnings Preview
November 08, 2023
Via
Benzinga
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
February 14, 2024
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.
Via
InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
February 14, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
3 Penny Stocks to Buy for the Next Bull Run: February 2024
February 07, 2024
As the market pivots in 2024, dive into the dynamic world of penny stocks, revealing the top choices for February's exhilarating bull run.
Via
InvestorPlace
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
February 06, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
January 26, 2024
With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
December 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
December 04, 2023
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety...
Via
Benzinga
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
November 14, 2023
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder...
Via
Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
November 10, 2023
Via
Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From
Vistagen
Via
Business Wire
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
November 07, 2023
Via
Investor Brand Network
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
November 06, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.